Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 2, 2025
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief …
Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology
GlobeNewswire
·
April 2, 2025
WAYNE, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from …
Foundation for Sarcoidosis Research Joins with Walgreens, Cedars-Sinai to Provide Foothill Unity with Free N95 Masks to Protect Residence Cleaning Up from the Recent Los Angeles Wildfires
GlobeNewswire
·
April 2, 2025
CHICAGO, April 02, 2025 (GLOBE NEWSWIRE) -- As clean up continues from January’s devastating Los Angeles wildfires, the Foundation for Sarcoidosis Research (FSR) is joining with Walgreens, Cedars-Sinai, and Foothill Unity to provide community members with …
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs
GlobeNewswire
·
April 2, 2025
Financing led by new investor Bain Capital with participation from new investor Wellington Management and all existing investors Proceeds to support advancement of ATSN-201 through potential approval and launch as well as preclinical programs to treat …
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient
GlobeNewswire
·
April 2, 2025
Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks Treatment High Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary Medications With Patient’s Pruritus …
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy …
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 2, 2025
EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and …
Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System
GlobeNewswire
·
April 2, 2025
CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced …
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, …
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer …
Grove AI Welcomes Former Novartis, UCB, and Google Executives to Company Advisory Board
GlobeNewswire
·
April 2, 2025
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Grove AI, pioneer in life science automation using agentic AI, today announced the formation of its inaugural Advisory Board. Comprised of prominent leaders from pharmaceutical and technology sectors, the …
Moringa: Learn Why These Moringa Powder Supplements Are Transforming Energy, Immunity, and Overall Health
GlobeNewswire
·
April 2, 2025
LAS VEGAS, April 02, 2025 (GLOBE NEWSWIRE) -- Moringa Oleifera, often called the “Miracle Tree,” is rapidly gaining recognition in the U.S. as a superfood for its remarkable health benefits. From boosting daily energy levels to fortifying immune support, …
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewswire
·
April 2, 2025
FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of …
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
GlobeNewswire
·
April 2, 2025
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, …
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
April 2, 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of …
Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Quebec, April 02, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, and a leader …
Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien-être, ainsi qu'un acteur clé sur le …
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, …
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire
·
April 2, 2025
NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer …